John L. Higgins
2021
In 2021, John L. Higgins earned a total compensation of $9.6M as Chief Executive Officer at Ligand Pharmaceuticals, a 64% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $522,438 |
|---|---|
| Option Awards | $2,344,512 |
| Salary | $696,583 |
| Stock Awards | $6,016,298 |
| Other | $7,380 |
| Total | $9,587,211 |
Higgins received $6M in stock awards, accounting for 63% of the total pay in 2021.
Higgins also received $522.4K in non-equity incentive plan, $2.3M in option awards, $696.6K in salary and $7.4K in other compensation.
Rankings
In 2021, John L. Higgins' compensation ranked 1,113th out of 12,412 executives tracked by ExecPay. In other words, Higgins earned more than 91.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,113 out of 12,412 | 91st |
Division Manufacturing | 383 out of 5,498 | 93rd |
Major group Chemicals And Allied Products | 140 out of 2,374 | 94th |
Industry group Drugs | 117 out of 2,095 | 94th |
Industry Pharmaceutical Preparations | 78 out of 1,542 | 95th |
Source: SEC filing on April 22, 2022.
Higgins' colleagues
We found three more compensation records of executives who worked with John L. Higgins at Ligand Pharmaceuticals in 2021.